Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) dropped 6.5% during trading on Wednesday . The stock traded as low as $4.11 and last traded at $4.15. Approximately 1,462,722 shares traded hands during trading, a decline of 14% from the average daily volume of 1,706,118 shares. The stock had previously closed at $4.44.

Several brokerages recently weighed in on ZIOP. Zacks Investment Research lowered shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. BidaskClub lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, December 22nd. Laidlaw began coverage on shares of ZIOPHARM Oncology in a research report on Monday, April 1st. They set a “buy” rating and a $7.50 price objective on the stock. Finally, Lake Street Capital began coverage on shares of ZIOPHARM Oncology in a research report on Thursday, April 4th. They set a “buy” rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.85.

The stock has a market cap of $709.19 million, a price-to-earnings ratio of -8.65 and a beta of 2.63.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Equities analysts forecast that ZIOPHARM Oncology Inc. will post -0.32 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its position in ZIOPHARM Oncology by 30.6% during the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 6,054 shares in the last quarter. Northern Trust Corp raised its position in shares of ZIOPHARM Oncology by 0.5% in the fourth quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock valued at $3,081,000 after purchasing an additional 8,068 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of ZIOPHARM Oncology by 57.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 47,069 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 17,130 shares during the period. Amalgamated Bank bought a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $37,000. Finally, Allred Capital Management LLC bought a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $40,000. 38.01% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “ZIOPHARM Oncology (ZIOP) Shares Down 6.5%” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2019/04/17/ziopharm-oncology-ziop-shares-down-6-5.html.

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Featured Article: Key terms to understand channel trading

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.